Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea

Size: px
Start display at page:

Download "Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea"

Transcription

1 Zoliflodacin (ETX0914) for Uncomplicated Gonorrhoea Global Antibiotic Research and Development Partnership, Pasteur Institute, 29 February, 2016

2 Entasis Therapeutics - Introduction Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections Located in Waltham, MA, USA; established May 2015 Strong financial position with $40 MM Series A financing First-in-class Phase 2 drug candidate to cure uncomplicated gonorrhoea Proprietary discovery platform with the potential to deliver additional novel drug candidates Innovative chemistry, unique biological and mechanistic insights Highly experienced team with an impressive scientific and managerial track record 1

3 Entasis has a Highly Experienced Leadership Team Manos Perros, PhD, President and Chief Executive Officer Head of Infection imed and Site Head, AZ Boston Director, Novartis Institute for Tropical Diseases CSO, Antivirals, Pfizer; co-inventor of maraviroc, PhRMA Discovers Award 2010 & Prix Galien 2008 Michael Fitzgerald, Chief Financial Officer SVP & CFO, Link Medicine Corp. CFO, Hypnion Inc. Robin Isaacs, MD, Chief Medical Officer VP and Therapeutic Area Head, Vaccines/Infectious Diseases Clinical Development, Merck Oversight of development and approval of numerous anti-infective, antiviral and vaccine products John Mueller, PhD, Vice President Program Management & Early Development Senior Project Director, AstraZeneca Infection imed Senior Director & Biology Head, Antibacterial Research, Pfizer Alexion Pharmaceuticals Ruben Tommasi, PhD, Chief Scientific Officer Executive Director, Infectious Disease Chemistry, AstraZeneca Executive Director Infection Chemistry; Head, Hit to Lead Optimization & Chemogenetics, Novartis Co-inventor tipranavir Chris White, Chief Business Officer CBO, AMAG Pharmaceuticals Partner at management consulting firms A.T. Kearney and Accenture Antibiotic product manager, Merck 2

4 Zoliflodacin (ETX0914) Overview 3

5 Gonorrhea is an Area of Significant Unmet Need N. gonorrhoeae is an immediate public health threat Highly contagious with low rates of resistance sufficient to drive new treatment recommendations Resistance to cefixime (oral cephalosporin) >1% 1 ; not recommended for use by CDC since 2012 Resistance to ceftriaxone (injectable cephalosporin, current standard-ofcare) is growing A 2012 report from the WHO reported worldwide estimates of over 106MM new cases of gonorrhea in 2008, up from ~90MM new cases in 2005 If untreated/poorly treated, gonorrhea can lead to pelvic inflammatory disease, infertility, and epididymitis % of N. gonorrhoeae Isolates with Reduced Susceptibility to Extended-spectrum Cephalosporins 3, * 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% China Japan Europe US CDC 2013 STD surveillance, susceptibility rates in the United States 2. CDC Antibiotic Resistance Threats in the United States, Cole MJ, et al. Euro surveill 2014;19(45) Cole MJ, et al. BMC Infect Dis Zheng H, et al. Japan J Infect Dis 2014;67: Hamasuna R, et al Japan J Infect Dis 203;19:571-8 Gu et al. BMC Infect Dis :731 Hamasuna R, et al. J Infect Chemother 2015;21:1-6 CDC. STD Surveillance 2013.Atlanta, US Department of HHS * Includes oral cefixime and ceftriaxone 4

6 Magnitude of Global Gonorrhoea Threat WHO Region Incidence (per 1,000) Male Female Incidence (Millions of cases) African Americas South-East Asia European Eastern Mediterranean Western Pacific Derived from WHO

7 Resistance to extended-spectrum cephalosphorins is of great concern Territory % of N. gonorrhoeae Isolates with Reduced Susceptibility to Extended- Spectrum Cephalosporins *, 1 USA 0.9% Europe 4.5% China 21% * Includes cefixime and ceftriaxone 1 CDC 2013 STD surveillance, susceptibility rates in the US; CDC Antibiotic Resistance Threats in the US, 2013; Cole MJ, et al. Euro Surveill (45); Zheng H et al. Japan J Infect Dis :288-91; Hamasuna R et al Japan J Infect Dis :571-8; Hamasuna R et al J Infect Chemo :1-6 6

8 Zoliflodacin for Uncomplicated Gonorrhea Drug Profile First of a novel class of topoisomerase inhibitors against Neisseria gonorrhoeae Population CDC estimates 820,000 cases of gonorrhea per year Concerns of growing resistance in available therapies Zoliflodacin s unique resistance profile, excellent tolerability and oral dosing will differentiate it from other therapies Label / Indications One time oral therapy for eradication of infection Data to Date Status Next Steps Phase 1: Linear PK and well tolerated up to 4 grams Achieved exposures in excess of those required for efficacy Phase 2 conducted in partnership with NIAID; enrollment complete FDA and MHRA endorsed Phase 2 and 3 endpoints Phase 3 formulation development on track Initiate thorough QT study/relative bioequivalence of Phase 3 formulation 7

9 Zoliflodacin is a First-in-class Antibiotic for the Treatment of Uncomplicated Gonorrhoea Current standard of care faces emerging resistance Threat of resistance rated as Urgent by CDC Zoliflodacin is from a novel class, no pre-existing resistance 1 Zoliflodacin is orally bioavailable Oral treatment could expedite partner therapy, increasing commercial potential Zoliflodacin is generally well-tolerated up to 4g Designated QIDP* and granted Fast Track status by the US FDA 1. Responding to the challenge of untreatable gonorrhea: Zoliflodacin, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Basarab, G. et al. Nature Scientific Reports; September, 2015 * Qualified Infectious Disease Product 8

10 Zoliflodacin has the Best Microbiological Profile Against Contemporary Clinical Isolates of N. gonorrhoeae Lack of Cross Resistance to Other Antibiotic Classes Mechanism Distinct from Fluoroquinolones Cumulative % at Each MIC (µg/ml)* Compound >32 Zoliflodacin Ciprofloxacin Azithromycin Cefixime Ceftriaxone Susceptible Intermediate Resistant * The strains comprised 29 international gonococcal reference strains, including the 2008 WHO reference strains, 100 consecutive clinical Swedish gonococcal isolates obtained in 2013, and 121 isolates selected for their resistance phenotype. The collection included all of the currently described XDR gonococcal strains, additional isolates with in vitro and clinical ESC resistance, different types of ciprofloxacin resistance, and other high-level clinical resistance and multidrug resistance (MDR) to other antimicrobials previously used for treatment. (Jacobsson S. et al. Antimicrob. Agents Chemother :9:5585-8) 9

11 Development Plan for Zoliflodacin Phase 2 Safety & Efficacy Phase 2 Read-out Phase 3 Prep (TQT, Rel. Bio) Phase 3 Efficacy Phase 3 Read-out NDA Prep, Submission & Review Approval & Launch Phase 3 Trial Design Multi-center, randomized, open-label Approximately 600 patients (2:1) Non-inferiority vs. ceftriaxone 500mg I.M. Primary endpoint: Microbiologic eradication Partnering strategy being evaluated 10

12 Zoliflodacin offers a medical breakthrough in the management of uncomplicated gonorrhea Product s Characteristics Oral Therapy for Gonorrhea Eradication Benefits Avoids painful intramuscular injections No need for crash cart or patient monitoring following treatment Opportunity to treat both the patient & their partner Novel Mechanism of Action Lack of pre-existing clinical resistance limits concerns about treatment failure One Time Treatment Single visit for treatment 11

13 Entasis Therapeutics is seeking a partner to support the Phase 3 clinical development program of zoliflodacin Phase 2 study has completed enrollment Licensure in the US and in the EU will require a single Phase 3 study Approximately 600 patients Approximately months from first patient enrolled to final clinical study report (approximately 13-months to enrol) Preliminary assessment does not predict significant ethnic sensitivity Results from clinical program in developed world should be directly relevant to low/middle-income areas 12

14 Questions? 13

6. Gonococcal antimicrobial susceptibility

6. Gonococcal antimicrobial susceptibility 6. Gonococcal antimicrobial susceptibility Key points Gonococcal AMR continues to increase worldwide and could lead to a pandemic of extensively drug-resistant (XDR) N. gonorrhoeae with serious public

More information

Developing a new drug for Sexually Transmitted Infections

Developing a new drug for Sexually Transmitted Infections Developing a new drug for Sexually Transmitted Infections Emilie Alirol, PhD Antimicrobial Chemotherapy Conference, 15 January 2019 Royal College of Physicians, London Content Global burden of Sexually

More information

Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham

Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology

More information

RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance

RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance Ina Park, MD, MS University of California San Francisco California Prevention Training Center DISCLOSURE No Relevant

More information

STD UPDATE Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018

STD UPDATE Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018 Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018 MISSION Improve health outcomes in communities disproportionately impacted by HIV and STDs Collect, study and publish data Diagnose and

More information

Internationell utblick STI/HIV i världen

Internationell utblick STI/HIV i världen Internationell utblick STI/HIV i världen Magnus Unemo, PhD, Assoc. Professor, Director Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology Örebro University

More information

Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae

Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae International Journal of Antimicrobial Agents 31S (2008) S35 S39 Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae T. Matsumoto Department of Urology, School

More information

Trends in Reportable Sexually Transmitted Diseases in the United States, 2007

Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public

More information

In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae

In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment

More information

Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes

Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Cécile Bébéar French National Center for bacterial STIs Bordeaux University

More information

CDC Grand Rounds: The Growing Threat of Multidrug-

CDC Grand Rounds: The Growing Threat of Multidrug- Page 1 of 8 Morbidity and Mortality Weekly Report (MMWR) CDC Grand Rounds: The Growing Threat of Multidrug- Resistant Gonorrhea Weekly February 15, 2013 / 62(06);103-106 Although gonorrhea has afflicted

More information

The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea

The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea Robert D. Kirkcaldy, MD, MPH Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, TB and STD Prevention Centers

More information

The objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and

The objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and 1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship

More information

Strategic priority to fight AMR

Strategic priority to fight AMR Strategic priority to fight AMR Launching a new program MRC meeting London 5 July 2017 Wellcome s framework for supporting science Advancing ideas We support great ideas and inspired thinking Seizing opportunities

More information

Management of Gonorrhea in Adolescents and Adults in the United States

Management of Gonorrhea in Adolescents and Adults in the United States SUPPLEMENT ARTICLE Management of Gonorrhea in Adolescents and Adults in the United States Sarah Kidd 1 and Kimberly A. Workowski 1,2 1 Division of STD Prevention, Centers for Disease Control and Prevention,

More information

The Gonococcal Antimicrobial Surveillance Program (GASP): A snapshot from Southern Africa Dumisile Venessa Maseko

The Gonococcal Antimicrobial Surveillance Program (GASP): A snapshot from Southern Africa Dumisile Venessa Maseko The Gonococcal Antimicrobial Surveillance Program (GASP): A snapshot from Southern Africa Dumisile Venessa Maseko Centre for HIV and STIs Na9onal Ins9tute for Communicable Diseases, Na9onal Health Laboratory

More information

Gonorrhea Antimicrobial Resistance in Alberta. Gonorrhea Antimicrobial Resistance Review

Gonorrhea Antimicrobial Resistance in Alberta. Gonorrhea Antimicrobial Resistance Review 2011 Review in Alberta Alberta Gonorrhea AMR Surveillance Working Group November 2013 2011 Review Background Gonorrhea remains one of the oldest infections known to man. Infections can result in significant

More information

Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar

Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar French Na*onal Center for bacterial STIs Bordeaux University hospital, Bordeaux, France University of Bordeaux,

More information

Antibiotics to treat multi-drug-resistant bacterial infections

Antibiotics to treat multi-drug-resistant bacterial infections Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements

More information

Antimicrobial resistance Fact sheet N 194 Updated April 2014

Antimicrobial resistance Fact sheet N 194 Updated April 2014 Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by

More information

Neisseria gonorrhoeae: The Ontario perspective. Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015

Neisseria gonorrhoeae: The Ontario perspective. Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015 Neisseria gonorrhoeae: The Ontario perspective Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015 Objectives Participants will be able to: Describe preferred specimen collection for testing

More information

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.? BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection

More information

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea Original Article Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H., Byron E. Batteiger, M.D., Edward W. Hook, III, M.D.,

More information

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation Stephanie N Taylor, Louisiana State University David H Morris, Desert AIDS Project

More information

Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A

Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A Record Status This is a critical abstract of an economic evaluation that meets the

More information

Drug-resistant Tuberculosis

Drug-resistant Tuberculosis page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of

More information

Sexually Transmitted Disease Surveillance 1998 Supplement

Sexually Transmitted Disease Surveillance 1998 Supplement Sexually Transmitted Disease Surveillance 1998 Supplement Division of STD Prevention November 1999 Gonococcal Isolate Surveillance Project (GISP) Annual Report - 1998 DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business

More information

Answers to those burning questions -

Answers to those burning questions - Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address

More information

REPRODUCTIVE TRACT INFECTIONS

REPRODUCTIVE TRACT INFECTIONS REPRODUCTIVE TRACT INFECTIONS State-of-the-Art 02.10.1998 Dr Saloney Nazeer Department of Gynaecology & Obstetrics Geneva University Hospital CLASSIFICATION OF RTIs STDs Non-STDs - infections which result

More information

Treatment resistant STIs relevant to MSM

Treatment resistant STIs relevant to MSM Treatment resistant STIs relevant to MSM David A. Lewis FRCP (UK) PhD Centre for HIV and STIs National Institute for Communicable Diseases (NHLS) Johannesburg, South Africa Regional Director, IUSTI Africa

More information

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Division of Infectious Diseases University of Alabama at Birmingham School of Medicine Birmingham, Alabama Outline Syphilis in all its

More information

Chlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University

Chlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Vaccine Innovation and Adult Immunization Landscape

Vaccine Innovation and Adult Immunization Landscape Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org

More information

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC), This document is scheduled to be published in the Federal Register on 11/16/2017 and available online at https://federalregister.gov/d/2017-24804, and on FDsys.gov BILLING CODE: 4163-18-P DEPARTMENT OF

More information

Sexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011

Sexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011 Sexually Transmitted Infection surveillance in Northern Ireland 2012 An analysis of data for the calendar year 2011 Contents Page Summary points. 3 Surveillance arrangements and sources of data.. 4 1:

More information

N A S D A Q : E V F M

N A S D A Q : E V F M N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform

More information

Management Presentation. January 2019

Management Presentation. January 2019 Management Presentation January 2019 Forward Looking Statements The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirusinfections,

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

LEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE

LEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE WHITE PAPER LEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE Over the past 15 years, the FDA and Congress developed several accelerated pathways to provide incentives for manufacturers to develop

More information

Okinawa, Toyako, and Beyond: Progress on Health and Development

Okinawa, Toyako, and Beyond: Progress on Health and Development Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,

More information

The WHO END-TB Strategy

The WHO END-TB Strategy ENDING TB and MDR-TB The WHO END-TB Strategy Dr Mario RAVIGLIONE Director Joint GDI/GLI Partners Forum WHO Geneva, 27 April 2015 This talk will deal with TB Burden Progress, Challenges Way Forward Who

More information

Research goal is to identify better diagnostic, vaccine and treatment targets for chlamydia and gonorrhea

Research goal is to identify better diagnostic, vaccine and treatment targets for chlamydia and gonorrhea FOR IMMEDIATE RELEASE Contact: Chris Hardwick SOM Office of Public Affairs 410-706-5260 UNIVERSITY OF MARYLAND SCHOOLS OF DENTISTRY AND MEDICINE RECEIVE $10.7M GRANT TO CONDUCT SYSTEMS BIOLOGY RESEARCH

More information

Global, National, Regional

Global, National, Regional Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology

More information

Dynavax Corporate Presentation

Dynavax Corporate Presentation Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,

More information

Acidform Vaginal Gel Contraception and STI Prevention

Acidform Vaginal Gel Contraception and STI Prevention Acidform Vaginal Gel Contraception and STI Prevention Empower Women. Change the World. David R. Friend, PhD Sr VP, R & D 1 Acidform Gel Acidform is a viscous, acidic (ph 3.5) gel with a high buffering

More information

Rotavirus: WHO Global Recommendations, Policy, and Surveillance

Rotavirus: WHO Global Recommendations, Policy, and Surveillance Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:

More information

Global, National, Regional

Global, National, Regional Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology

More information

Business Update & Financial Results for Q1 2018

Business Update & Financial Results for Q1 2018 Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma

More information

Validation of the MALDI-TOF for the Identification of Neisseria gonorrhoeae

Validation of the MALDI-TOF for the Identification of Neisseria gonorrhoeae Proposal Validation of the MALDI-TOF for the Identification of Neisseria gonorrhoeae Laboratory Director Sandip H. Shah, Ph.D. 517-335-8063 517-335-8051 (fax) ShahS@Michigan.gov Acting Director, Division

More information

The CLSI Approach to Setting Breakpoints

The CLSI Approach to Setting Breakpoints The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic

More information

Index. Infect Dis Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

Index. Infect Dis Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type. Infect Dis Clin N Am 19 (2005) 563 568 Index Note: Page numbers of article titles are in boldface type. A Abstinence in genital herpes management, 436 Abuse sexual childhood sexual behavior effects of,

More information

Management Presentation. June 2017

Management Presentation. June 2017 Management Presentation June 2017 Forward Looking Statements The statements made in this presentation may include forward-looking statements regarding the treatment of orthopoxvirus infections, the development

More information

Dual Therapy: Symptoms and Screening:

Dual Therapy: Symptoms and Screening: 5. Gonorrhea Gonorrhea is caused by Neisseria gonorrhoeae, a bacterium that can grow and multiply in the warm, moist areas of the reproductive tract, including the cervix (opening to the womb), uterus

More information

2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing

2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing 2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing Joan M. Chow, MPH, DrPH Surveillance, Epidemiology, Assessment & Evaluation Section Sexually Transmitted Disease Control Branch Division

More information

News Release. December 9, Not intended for UK-based media

News Release. December 9, Not intended for UK-based media Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72-9591 Investor Relations: +49 6151 72-3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160

More information

Below is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:

Below is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017: SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM

More information

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations

More information

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education

More information

Sexually Transmitted Infection Treatment and HIV Prevention

Sexually Transmitted Infection Treatment and HIV Prevention Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.

More information

California Almonds: Creating Demand and Value

California Almonds: Creating Demand and Value California Almonds: Creating Demand and Value Julie G. Adams NUCIS ITALIA Conference at Marca 2011 19 January 2011 1 Case Study in 15 minutes! About the Almond Board About the Almond Industry Global Strategy:

More information

WHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections

WHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections

More information

Pierre Legault CEO June 2, 2014

Pierre Legault CEO June 2, 2014 April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE OBJECTIVES FOR PHARMACISTS GOAL

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE OBJECTIVES FOR PHARMACISTS GOAL DISCLOSURE PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES Dr. Feller does not have any actual or potential conflicts of interest to disclose and will not be discussing

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

Oragenics Shareholder Update

Oragenics Shareholder Update January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),

More information

Recent Trends in Neisseria gonorrhoeae Infection

Recent Trends in Neisseria gonorrhoeae Infection Sexually Transmitted Diseases Recent Trends in Neisseria gonorrhoeae Infection JMAJ 45(12): 499 505, 2002 Shoichi ONODERA Professor, Department of Urology, The Jikei University School of Medicine Abstract:

More information

Emerging Issues in STDs and Resistance

Emerging Issues in STDs and Resistance Emerging Issues in STDs and Resistance Toye H. Brewer, MD Asst. Professor of Clinical Medicine University of Miami School of Medicine Co-Director- Fogarty International Training Program Outline Syphilis-

More information

CANCER FACT SHEETS: BREAST CANCER

CANCER FACT SHEETS: BREAST CANCER CANCER FACT SHEETS: BREAST CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance WHO South-East Asia Region More developed regions WHO African Region WHO Region of the

More information

Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and

Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations

More information

Why can t we eliminate tuberculosis?

Why can t we eliminate tuberculosis? Why can t we eliminate tuberculosis? Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Chief Scientific Officer World Lung Foundation Current

More information

Positioned for Growth

Positioned for Growth Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation

More information

SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization

SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization WHO COLLABORATING CENTRE FOR RESEARCH IN HUMAN REPRODUCTION Hôpitaux Universitaires de Genève SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization Dr SALONEY NAZEER Department of Gynaecology

More information

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

Novel pena mutations identified in Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone isolated between 2000 and 2014 in Japan

Novel pena mutations identified in Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone isolated between 2000 and 2014 in Japan J Antimicrob Chemother 2016; 71: 2466 2470 doi:10.1093/jac/dkw161 Advance Access publication 13 May 2016 Novel pena mutations identified in Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone

More information

Meeting Report. 7 9 April 2010 Manila, Philippines

Meeting Report. 7 9 April 2010 Manila, Philippines Meeting Report Consultation on the Strategic Response to the Threat of Untreatable Neisseria gonorrhoeae and Emergence of Cephalosporin Resistance in Neisseria gonorrhoeae 7 9 April 2010 Manila, Philippines

More information

Castle Creek Pharmaceuticals

Castle Creek Pharmaceuticals Castle Creek Pharmaceuticals Dermatology Summit Entrepreneurial Showcase 2018 Michael Derby, CEO January 7, 2018 Castle Creek Pharma Driving innovation in dermatology We are a high-growth biotech company

More information

TB epidemic and progress towards the Millennium Development Goals

TB epidemic and progress towards the Millennium Development Goals Open Forum 4: Key issues in TB Drug Development, August 18, 2010, Addis Ababa, Ethiopia TB epidemic and progress towards the Millennium Development Goals Haileyesus Getahun Stop TB Department, WHO Geneva,

More information

PIP Framework Information Session 10 April 2018

PIP Framework Information Session 10 April 2018 Pandemic Influenza Preparedness Framework Sharing of influenza viruses & access to vaccines and other benefits PIP Framework Information Session 10 April 2018 PIP Framework Information Session Purpose:

More information

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE GOAL

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE GOAL PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES Jade Feller, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System November 13, 2018 DISCLOSURE

More information

February 23, Q4 and Year-End 2016 Financial Results

February 23, Q4 and Year-End 2016 Financial Results February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,

More information

Best Practices in STD Partner Management

Best Practices in STD Partner Management Best Practices in STD Partner Management An Overview of Patient-Delivered Partner Therapy (PDPT) and Counseling for Partner Notification and Treatment Amber Eisenmann, MS Director of Learning Exchange

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

STI in British Columbia: Annual Surveillance Report

STI in British Columbia: Annual Surveillance Report STI in British Columbia: Annual Surveillance Report 212 Contact Information BC Centre for Disease Control Clinical Prevention Services 655 West 12th Avenue Vancouver BC V5Z 4R4 Phone: 64-77-5621 Fax: 66-77-564

More information

NOVEL MEDICATION FOR NEUROPATHIC PAIN

NOVEL MEDICATION FOR NEUROPATHIC PAIN NOVEL MEDICATION FOR NEUROPATHIC PAIN NRD.E1 a treatment for diabetic related neuropathic pain Novaremed s Dr Eli Kaplan shares research on NRD.E1 and explains how it can help to treat diabetic related

More information

Appendix B Recommendation for enhanced surveillance of gonococcal infection

Appendix B Recommendation for enhanced surveillance of gonococcal infection Appendix B Recommendation for enhanced surveillance of gonococcal infection Enhanced gonococcal infection surveillance Recommendation for enhanced surveillance of gonorrhoea in the context of the increase

More information

Update on Treatment Options for Gonococcal Infections

Update on Treatment Options for Gonococcal Infections Update on Treatment Options for Gonococcal Infections Jason W. Lancaster, 1,2, * Monica V. Mahoney, 3 Sana Mandal, 1 and Kenneth R. Lawrence, 4 1 School of Pharmacy, Northeastern University, Boston, Massachusetts;

More information

Sexually Transmi/ed Diseases

Sexually Transmi/ed Diseases Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human

More information

Fact sheet. Poliomyelitis. WHO Media centre. ADAPTED FOR ADDITION TO THE RHIZOME POLIOK.IT PLATFORM 16 Jan 2017 INFORMATION FOR ERADICATION FROM

Fact sheet. Poliomyelitis. WHO Media centre. ADAPTED FOR ADDITION TO THE RHIZOME POLIOK.IT PLATFORM 16 Jan 2017 INFORMATION FOR ERADICATION FROM Fact sheet Poliomyelitis WHO Media centre ADAPTED FOR ADDITION TO THE RHIZOME POLIOK.IT PLATFORM 16 Jan 2017 INFORMATION FOR ERADICATION FROM Media centre Poliomyelitis Fact sheet Updated April 2016 Key

More information

Innovative Nuclear Receptor Modulation Medicine

Innovative Nuclear Receptor Modulation Medicine Innovative Nuclear Receptor Modulation Medicine Dale C Leitman, M.D., Ph.D. Isaac Cohen, O.M.D., Ph.D. October 2015 Corporate Mission Iaterion, Inc. is Developing Novel Pharmaceutical Nuclear Receptor

More information

Developing the next generation of infection and immunity leaders. The Peter Doherty Institute for Infection and Immunity

Developing the next generation of infection and immunity leaders. The Peter Doherty Institute for Infection and Immunity Developing the next generation of infection and immunity leaders The Peter Doherty Institute for Infection and Immunity Nobody can decide to discover something, but there are ways of making a discovery

More information

For personal use only

For personal use only Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development

More information

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 1 Objectives of today s lecture Describe global goals in the fight against HIV Review the epidemiology

More information

The Local Health Performance Incentive Program: Year 3. Office of Public Health Practice

The Local Health Performance Incentive Program: Year 3. Office of Public Health Practice The Local Health Performance Incentive Program: Year 3 Office of Public Health Practice Background & General Program Overview Christopher Davis, PhD Office of Public Health Practice 3 Background In 2012

More information

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee

More information

SUPERBUGS THE ROLE OF DIAGNOSTICS EXPLAINED

SUPERBUGS THE ROLE OF DIAGNOSTICS EXPLAINED & SUPERBUGS THE ROLE OF DIAGNOSTICS EXPLAINED 1 of 17 Superbugs are microorganisms resistant to drugs that were previously effective. Before resistance After resistance 2 of 17 WHAT S MAKING THE PROBLEM

More information

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case

More information